期刊
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
卷 9, 期 6, 页码 423-430出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920108786786358
关键词
Monoclonal antibodies; success rates; clinical study; Food and Drug Administration; marketing approval; benchmarks
Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in clinical development because of their versatility as therapeutic agents. While traditionally associated with the biotechnology industry, mAb therapeutics are now being developed and marketed by most major pharmaceutical firms. A total of 21 products are approved in the US, with additional products marketed outside the US, and over 200 mAb candidates are currently undergoing clinical study. Benchmark data for mAb therapeutics, such as clinical development and US Food and Drug Administration approval times, approval success rates, and clinical phase transition probabilities, are critical for strategic planning purposes. Trends in these benchmarks for various types of mAbs, with an emphasis on those studied as anticancer and immunological therapeutics, are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据